Concha-Benavente Fernando, Ferris Robert L
Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Curr Opin Immunol. 2017 Apr;45:52-59. doi: 10.1016/j.coi.2017.01.004. Epub 2017 Feb 14.
Unrestrained growth factor signals can promote carcinogenesis, as well as other hallmarks of cancer such as immune evasion. Our understanding of the function and complex regulation of HER family of receptors has led to the development of targeted therapeutic agents that suppress tumor growth. However, these receptors also mediate escape from recognition by the host immune system. We discuss how HER family of oncogenic receptors downregulate tumor antigen presentation and upregulate suppressive membrane-bound or soluble secreted inhibitory molecules that ultimately lead to impaired cellular immunity mediated by cytotoxic T lymphocyte (CTL) recognition. Implementing this knowledge into new therapeutic strategies to enhance tumor immunogenicity may restore effector cell mediated immune clearance of tumors and clinical efficacy of tumor-targeted immunotherapy against HER receptor overexpression.
不受抑制的生长因子信号可促进癌症发生,以及癌症的其他特征,如免疫逃逸。我们对HER受体家族功能和复杂调控的理解,促使了抑制肿瘤生长的靶向治疗药物的研发。然而,这些受体也介导肿瘤逃避宿主免疫系统的识别。我们讨论了致癌HER受体家族如何下调肿瘤抗原呈递,并上调抑制性膜结合或可溶性分泌抑制分子,最终导致细胞毒性T淋巴细胞(CTL)识别介导的细胞免疫受损。将这一知识应用于新的治疗策略以增强肿瘤免疫原性,可能会恢复效应细胞介导的肿瘤免疫清除,以及针对HER受体过表达的肿瘤靶向免疫治疗的临床疗效。